Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836119 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL786679 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL26594 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL12764464 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL2187341 | 0.79 | — | — | |
| SCHEMBL419264 | 0.79 | CA12 (0.54) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL4236 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL5485891 | 0.77 | SMN1; SMN2 (0.90) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL13921120 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL6040035 | 0.77 | MEN1 (0.62) | SMN1; SMN2CA12CA1CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540366-B2 | Ring-fused heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9382188-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-9381200-B2 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-8822450-B2 | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LTD. (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2314598-A1 | Inhibitors of Hepatitis C virus NS3 serine protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-4304931-A | ANTIINFLAMMATORY AGENTS | THE BOOTS COMPANY LIMITED (GB) | 1981-12-08 | — | — | US | disclosed |
| US-4188491-A | PREPARING 2-(4-BIPHENYLYL)PROPIONIC ACIDS BY REACTING BIPHENYLYLMAGNESIUM BROMIDES WITH SODIUM PYRUVATE, ACIDIFYING | THE BOOTS COMPANY LIMITED (GB) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | SMN1; SMN2 2731/4885CA12 2298/4885CA1 2734/4885 |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | SMN1; SMN2 664/4885CA12 514/4885CA1 214/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4705/4885CA12 4571/4885CA1 4815/4885 |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | ODC1, AOC1, CASP7 | SMN1; SMN2 2528/4885CA12 3988/4885CA1 4621/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4705/4885CA12 4571/4885CA1 4815/4885 |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | SMN1; SMN2 2188/4885CA12 2558/4885CA1 3044/4885 |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | SMN1; SMN2 2259/4885CA12 1700/4885CA1 1528/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | SMN1; SMN2 2032/4885CA12 3021/4885CA1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.